Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice

Incretin therapy has emerged as one of the most popular medications for type 2 diabetes. We have previously reported that the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin attenuates neointima formation after vascular injury in non-diabetic mice. In the present study, we examined whether comb...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hiroyuki Takahashi, Takashi Nomiyama, Yuichi Terawaki, Takeshi Horikawa, Takako Kawanami, Yuriko Hamaguchi, Tomoko Tanaka, Ryoko Motonaga, Takashi Fukuda, Makito Tanabe, Toshihiko Yanase
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2019-07-01
Colecção:	Biochemistry and Biophysics Reports
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2405580818302668
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!